StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Pfizer (PFE). Eli Lilly & Co. (NYSE:LLY) Report Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis
April 18, 2019 5:06 PM
Pfizer Inc. (NYSE: PFE) and Eli Lilly and Company (NYSE: LLY) today announced top-line results from a Phase 3 study ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Hot Corp. News
Hot FDA News
Management Comments
Next Articles
Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis
April 18, 2019 5:05 PM
Merck (MRK), Lilly (LLY), Pfizer (PFE) Weakness Continues as Biotech Shares Get Hit Again
April 18, 2019 10:23 AM
Merck (MRK), Pfizer (PFE) Lilly (LLY) Shares Decline Amid Biotech Weakness
April 17, 2019 10:26 AM